Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00778609
Recruitment Status : Completed
First Posted : October 23, 2008
Last Update Posted : January 14, 2016
Information provided by (Responsible Party):

Brief Summary:
The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle compared to a commonly used contraceptive pill (Microgynon).

Condition or disease Intervention/treatment Phase
Oral Contraceptive Headache Pelvic Pain Drug: EV/DNG (Qlaira, BAY86-5027) Drug: Encapsulated Microgynon + Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 449 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment
Study Start Date : December 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: EV/DNG (Qlaira, BAY86-5027)
Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval

Active Comparator: Arm 2 Drug: Encapsulated Microgynon + Placebo
Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo

Primary Outcome Measures :
  1. To compare SH T00658ID (Qlaira) to Microgynon with regard to changes in frequency and intensity of the hormone withdrawal associated symptoms headache and pelvic pain on cycle days 22-28 combined into a single endpoint [ Time Frame: Baseline to cycle 6 ]

Secondary Outcome Measures :
  1. Rescue medication consumption [ Time Frame: Baseline to cycle 6 ]
  2. Frequency and intensity of other hormone-related symptoms (bloating or swelling, breast tenderness, and nausea or vomiting) during cycle days 22 to 28 [ Time Frame: Baseline to cycle 6 ]
  3. Prevalence of individual hormone-related symptoms during cycle days 1 to 21 [ Time Frame: Baseline to cycle 6 ]
  4. Prevalence of individual hormone-related symptoms during hormone-free interval, i.e. cycle days 27+28 for EV/DNG capsules and cycle days 22 to 28 for the comparator [ Time Frame: Baseline, cycle 3 and cycle 6 ]
  5. Change in the average of the 3 highest VAS values of the hormone withdrawal associated symptoms pelvic pain or headache during cycle days 22 to 28 from baseline to cycle 3 [ Time Frame: Baseline to cycle 3 ]
  6. Bleeding pattern and cycle control [ Time Frame: Throughout ]
  7. QoL Questionnaires: Psychological General Well-Being Index (PGWBI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Clinical Global Index (CGI) [ Time Frame: Baseline, cycle 2 and cycle 5 ]
  8. AEs and SAEs. Concomitant medication. Vital signs (heart rate and blood pressure). Body weight [ Time Frame: Throughout ]
  9. General physical and gynecological examination [ Time Frame: Screening and Final Visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 18 and 50 years (inclusive) at visit 1, for smokers up to 35 years (inclusive)
  • Otherwise healthy female subjects requesting contraception and currently using a levonorgestrel, gestodene or desogestrel containing oral contraceptive in a 21-day regimen and suffering from at least moderate pelvic pain, headache or both defined by an average value of >/= 35 mm for the 3 highest values on a visual analogue scale during cycle days 22-28.
  • Normal or clinically insignificant cervical smear not requiring further follow up (or a normal result obtained within the last 6 months before screening)
  • Able to tolerate ibuprofen and willing to use only ibuprofen supplied for the study.

Exclusion Criteria:

  • Women with any contraindication for oral contraceptive use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00778609

Show Show 63 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00778609    
Other Study ID Numbers: 91550
310787 ( Other Identifier: Company Internal )
2008-003226-42 ( EudraCT Number )
First Posted: October 23, 2008    Key Record Dates
Last Update Posted: January 14, 2016
Last Verified: January 2016
Keywords provided by Bayer:
Combined Oral Contraceptives
Pelvic Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Pelvic Pain
Neurologic Manifestations
Ethinyl estradiol, levonorgestrel drug combination
Ethinyl Estradiol-Norgestrel Combination
Contraceptive Agents, Hormonal
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptives, Oral, Hormonal
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital, Hormonal
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic